Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Medicina Clinica|July 19, 2016
[Mechanism of action and preclinical development of afatinib]Pilar Diz Taín, Ana López González, Andrés García-Palomo
Medical Oncology (Northwood, London, England)|October 7, 2010
Activity of trabectidin in desmoplastic small round cell tumorAna López-González, Blanca Cantos, Eva Tejerina, et al.
Revista De Enfermeria (Barcelona, Spain)|September 28, 2018
[Central Venous Catheters with Subcutaneous Reservoir with Implementation Braquial: An Alternative to Consider]J Alfonso Álvarez Rodríguez, Ana López González, Luzdivina Álvarez Rodríguez, et al.
Annals of Translational Medicine|October 22, 2014
The role of anthracyclines in small cell lung cancerAna López-González, Pilar Diz, Lourdes Gutierrez, et al.
Atencion Primaria|January 8, 2011
[Prostate cancer, antiandrogen treatment and cardiovascular risk]Santiago Reinoso Hermida, Gabriel J Díaz Grávalos, Aida Robles Castiñeiras, et al.
Revista Espanola De Geriatria Y Gerontologia|May 15, 2012
[Prevalence of neuropsychiatric symptoms and associated factors in institutionalised dementia patients: A multicentre cross-sectional study]Aida Robles Castiñeiras, Gabriel J Díaz Grávalos, Santiago Reinoso Hermida, et al.
Archivos Espanoles De Urologia|November 25, 2010
Natural progression of embryonal carcinomaAna López-González, María Alejandra Egui Rojo, Constanza Maximiano, et al.
Future Oncology (London, England)|April 4, 2018
Experience with eribulin in HR+/HER2- metastatic breast cancer, including a maleMaria Del Mar Muñoz Sánchez, Maria Del Carmen Soriano Rodríguez, Maria José Molina Garrido, et al.
Cancers|September 23, 2022
Relationship between Aldehyde Dehydrogenase, PD-L1 and Tumor-Infiltrating Lymphocytes with Pathologic Response and Survival in Breast CancerMariana López Flores, Emiliano Honrado Franco, Luis Felipe Sánchez Cousido, et al.
Cancer Treatment and Research Communications|November 23, 2023
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)Silvia Antolín Novoa, Santiago Escrivá-de-Romaní, Pablo Tolosa Ortega, et al.
Pageof 2